Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Horizon Therapeutics Public Ltd Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 39.67%. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:
The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.44 years is 0.45%; that's better than 75.06% of cash flow producing equities in the Healthcare sector, where it is classified.
The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than just 17.65% of the free cash flow producing stocks we're observing.
Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 115 -- greater than 97.73% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
EDAP, GSK, OSMT, PRGO, and MD can be thought of as valuation peers to HZNP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460]. Horizon’s MIRROR clinical program includes the completed multi-center, open-label trial as well as an ongoing randomized controlled trial (RCT). The tri
Horizon Therapeutics jumped Tuesday after a huge gain Monday. Cleared 79.03 traditional buy point intraday, probably could have bought at 77.46 s-term high and perhaps even earlier with a downward sloping line. RS line at new high. Second straight gain in above-avg volume.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes. Over 100 years of market history shows that the best stocks tend to have an 80 or higher RS Rating as they begin their biggest climbs.